Search for a trial

Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D)

To determine whether aleglitazar reduces cardiovasculair mortality and morbidity (defined as non-fatal myocardial infarction (MI) and non-fatal stroke) in patients with a recent ACS event and type 2 diabetes.

Immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial parvovirus B19 persistence - a prospective, double-blind, randomized, placebo-controlled clinical trial

A controlled trial to investigate whether high dose of intravenous immunoglobulin (IVIg) in addition to conventional heart failure therapy in patients with idiopathic cardiomyopathy and PVB19 persistence in the heart achieves improvement of cardiac…

Acute and chronic administration of the folate derivate levofolinate to patients with acute myocardial infarction: A double-blinded placebo-controlled pilot study.
"Folate in Acute Myocardial Infarction (FolAMI-study)"

A controlled trial to investigate whether by reducing eNOS uncoupling, by direct super oxide scavenging and by up regulating the high-energy phosphate pool, a high dose of intravenous levofolinate can reduce ischemia- and reperfusion-induced…

A clinical trial comparing treatment with cangrelor (in combination with usual care) to usual care, in subjects who require percutaneous coronary intervention

The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a composite of all-cause…

The effect of two different heart-lung machines, Twin-Pulse Life Support and standard used heart-lung machine, on the systemic inflammation and pattern of microvascular blood flow. A prospective randomised clinical trial.

Analysis of the effects of the Twin-Pulse Life Support on on the systemic inflammatory response and the effect on microvascular blood flow in ocmparison to standard used Extracorporeal Circuit Device

Extension 1 to Protocol
A 2 year extension to a 36-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in high risk post-acute myocardial infarction patients when added to optimized standard therapy

The primary objective of this 2 year extension study (CSPP100A2340E1) is to provide additional long-term safety data in this patient population as a post marketing commitment to the EMEA. A secondary objective is to provide additional follow-up data…

A 36 week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in high risk post-acute myocardial infarct patients when added to optimized standard therapy

The primary objective of this trial is to demonstrate that aliskiren 300 mg, in addition to standard therapy, has superior efficacy compared to placebo in reducing the primary index of adverse cardiac remodeling (defined as the change in LVESV from…

A multicentre, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of daily oral dosing of tafamidis meglumine (PF-06291826) 20 mg or 80 mg in comparison to placebo in subjects diagnosed with transthyretin cardiomyopathy (TTR-CM).

The objective of this study is to determine the efficacy, safety, and tolerability of tafamidis in subjects with transthyretin cardiomyopathy.The primary objective is to assess the efficacy, safety, and tolerability of an oral dose of 20 mg or 80 mg…

PHOspholamban RElated CArdiomyopathy STudy - intervention (i-PHORECAST)

The primary objective is to show that eplerenone treatment reduces progression of disease in presymptomatic PLN R14del-carriers

Bivalirudin Infusion for Ventricular Infarction Limitation

The study hypothesis is that anticoagulation with bivalirudin for primary PCI in STEMI subjects with a 4 h infusion post-PCI will reduce infarct size compared with anticoagulation with UFH as assessed by CMR 5 days after the index event.The primary…

The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BMMNC) on all causemortality in acute myocardial infarction

To demonstrate that a single intracoronary infusion of autologous bone marrow-derived mononuclear cells in addition to state of the art treatment is safe and reduces allcause mortality in patients with reduced left ventricular ejection fraction (…

A multi-center, randomized, double-blind, active-controlled, parallelgroup Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk
patients following an acute myocardial infarction

The purpose of this study is to evaluate the efficacy and safety of LCZ696 compared to ramipril, in reducing the occurrence of cardiovascular (CV) death, heart failure (HF) hospitalization and outpatient HF (time-to-first event analysis) in post-AMI…

IOCYTE AMI-3: A Phase 3, Randomized, Double-Blind, Placebo- Controlled, Multicenter Study of Intravenous FDY-5301 in Patients with an Anterior ST-Elevation Myocardial Infarction

This study has been transitioned to CTIS with ID 2024-514372-40-00 check the CTIS register for the current data. Primary objective: To assess the effect of FDY-5301 on cardiovascular mortality and heart failure events in subjects with an anterior…

Multi-center, double-blind, randomized, placebo-controlled, parallel-group
study to evaluate the efficacy and safety of self-administered
subcutaneous selatogrel for prevention of all-cause death and treatment of
acute myocardial infarction in subjects with a recent history of acute
myocardial infarction

This study has been transitioned to CTIS with ID 2023-505438-85-00 check the CTIS register for the current data. The primary objective of the study is to assess the clinical efficacy of selatogrel when self-administered upon occurrence of…

EMPACT-MI: A streamlined, multicentre, randomised, parallel group, double-blind placebo-controlled superiority trial to evaluate the effect of EMPAgliflozin on hospitalisation for heart failure and mortality in patients with aCuTe Myocardial Infarction

The main objective of this event-driven trial is to demonstrate the superiority of empagliflozin 10 mg once daily versus placebo, in addition to standard of care, for the reduction of the composite endpoint of time to first heart failure…

A Phase 3 prospective, blinded, randomized, placebo controlled, international multicenter study to assess the safety and efficacy of a single subcutaneous injection of zalunfiban in subjects with ST-elevation myocardial infarction in the pre-hospital setting

This study has been transitioned to CTIS with ID 2023-508485-15-00 check the CTIS register for the current data. Main study:Primary:Efficacy:- To assess the clinical outcome at 30 days follow-up after administration of a single subcutaneous…

Surgical Septal Myectomy versus Percutaneous Transluminal Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy

The aim of this registry is to compare functional status among patients with highly symptomatic obstructive HCM despite optimal medical treatment who undergo Alcohol Septal Ablation to Surgical Septal Myectomy. This study will therefore, compare the…

A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients with Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation

In patients with symptomatic New York Heart Association (NYHA) Class II/III/IV dilated cardiomyopathy (DCM) in which mutations in the gene encoding the lamin A/C protein (LMNA) have been implicated:Primary Objective:* NYHA Class II/III patients only…

A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dacetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-GenE trial

The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality (cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction (MI) and non-fatal stroke) in…